Pharmaceutical compounds

Details Pharmaceutical compounds Pharmaceutical compounds

2005-05-23

2010-02-09

Stockton, Laura L. (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S326000, C514S406000, C546S211000, C548S364100

Reexamination Certificate

active

07659407

ABSTRACT:
Pyrazole derivatives of the following formula (I), having affinity for the cannabinoidergic CB1 and/or CB2 receptors:wherein:R is a group selected from:C1-C10alkyl;aryl, arylalkyl or arylalkenyl, not substituted or having from one to four substituents, equal to or different from each other;A is a group selected from the following:an ether group of formula —(CH2)—O—(CH2)v—R″ whereinv is equal to 1 or 2;R″ is as defined in the present application;a ketone group of formula —C(O)—Z′, wherein Z′ is as defined in the present application;a substituent having an hydroxyl function of formula —CH(OH)—Z′, Z′ being as defined in the present application;an amide substituent of formula —C(O)—NH—T′, T′ being as defined in the present application;B is a group as defined in the present application;D is an heteroaryl optionally substituted.

REFERENCES:
patent: 5462960 (1995-10-01), Barth et al.
patent: 5466823 (1995-11-01), Talley et al.
patent: 5504216 (1996-04-01), Holohan et al.
patent: 5508426 (1996-04-01), Holohan et al.
patent: 5510496 (1996-04-01), Talley et al.
patent: 5516907 (1996-05-01), Talley et al.
patent: 5521207 (1996-05-01), Graneto
patent: 5547975 (1996-08-01), Talley et al.
patent: 5563165 (1996-10-01), Talley et al.
patent: 5753688 (1998-05-01), Talley et al.
patent: 5756529 (1998-05-01), Isakson et al.
patent: 5760068 (1998-06-01), Talley et al.
patent: 5925768 (1999-07-01), Barth et al.
patent: 6028084 (2000-02-01), Barth et al.
patent: 6100259 (2000-08-01), Xiang et al.
patent: 6156781 (2000-12-01), Talley et al.
patent: 6217860 (2001-04-01), Woo et al.
patent: 6344474 (2002-02-01), Maruani et al.
patent: 6413960 (2002-07-01), Talley et al.
patent: 6432984 (2002-08-01), Barth et al.
patent: 6476060 (2002-11-01), Lange et al.
patent: 6492411 (2002-12-01), Talley et al.
patent: 6509367 (2003-01-01), Martin et al.
patent: 6586603 (2003-07-01), Talley et al.
patent: 6716991 (2004-04-01), Talley et al.
patent: 6951949 (2005-10-01), Talley et al.
patent: 7157470 (2007-01-01), Smallheer et al.
patent: 7393842 (2008-07-01), Makriyannis et al.
patent: 2001/0053788 (2001-12-01), Lange et al.
patent: 2003/0003145 (2003-01-01), Abramovici et al.
patent: 2004/0039024 (2004-02-01), Barth et al.
patent: 2004/0192667 (2004-09-01), Makriyannis et al.
patent: 2004/0192930 (2004-09-01), Talley et al.
patent: 2004/0204406 (2004-10-01), Nazare et al.
patent: 2005/0096379 (2005-05-01), Martin et al.
patent: 2005/0101592 (2005-05-01), Carpino et al.
patent: 2005/0131050 (2005-06-01), Talley et al.
patent: 2006/0030563 (2006-02-01), Makriyannis et al.
patent: 2006/0100208 (2006-05-01), Makriyannis et al.
patent: 102 39 832 (2004-03-01), None
patent: 0 477 049 (1992-03-01), None
patent: 0 656 354 (1995-06-01), None
patent: 0731795 (1999-12-01), None
patent: 1 216 980 (2002-06-01), None
patent: 1 230 222 (2002-08-01), None
patent: 1 230 244 (2002-08-01), None
patent: 0854723 (2003-04-01), None
patent: 1571147 (2005-09-01), None
patent: WO 95/15316 (1995-06-01), None
patent: WO 97/11704 (1997-04-01), None
patent: WO 01/29007 (2001-04-01), None
patent: WO 03/020217 (2003-03-01), None
patent: WO 03/026652 (2003-04-01), None
patent: WO 2004/016592 (2004-02-01), None
patent: WO 2004/056815 (2004-07-01), None
patent: WO 2005/016877 (2005-02-01), None
patent: WO 2005/063737 (2005-07-01), None
patent: WO 2006/076442 (2006-07-01), None
Gorbunova et al., CA 80:70640, 1974.
Souillac, et al., Characterization of Delivery Systems, Differential Scanning Calorimetry in Encyclopedia of Controlled Drug Delivery, 1999, John Wiley & Sons, pp. 212-227.
Vippagunta et al. (Advanced Drug Delivery Reviews, 48 (2001), pp. 3-26.
Q. Lu et al., “Expression of CB2 cannabinoid receptor mRNA in adult rat retina”,Visual Neurosciencecol17, 91-95, 2000.
M. Glass, “The Role of Cannabinoids in Neurodegenerative Diseases,”Prog. Neoro-Psychopharmacol.&Biol. Psychiatri. 25, 743-765, 2001.
A. Porcella et al., “Cannabinoid receptor CB1, mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marihuana1”,J. Pharmacol. Exp. Ther. 58, 240-245, 1998.
A. Porcella et al., “The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein”,European Journal of Neorosci12, 1-5, 2000.
M. Pacheco et al., “Aminoalkylindoles: Actions on Specific G-Protein-Linked Receptors1”,J. Pharmacol. Exp. Ther. 257, 170-182, 1991.
B.R. Martin et al., “Behavioral, Biochemical, and Molecular Modeling Evaluations of Cannabinoid Analogs”,Pharmacol. Biochem. Behav. 40, 471-478, 1991.
P.B. Smith et al., “The Pharmacological Activity of Anandamine, a Putative Endogenous Cannabinold, in Mice”,J. Pharmacol. Exp. Ther. 270, 219-227, 1994.
M. Rinaldi-Carmona et al., “SR 141716A, a potent and selective antagonist of the brain cannbinoid receptor”,FEBS Lett., 350, 240-244, 1994.
M. Rinaldi-Carmona at al., “SR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinold Receptor”,J. Pharmacol. Exp. Ther. 284, 644-650, 1998.
Remington: The Science and Practice of Pharmacy, II, 1457, 1995.
R.G. Pertwee, “Further evidence for the presence of cannabinoid Cb1receptors in guinea-pig small intestine”, Br. J. Pharmacol. 118, 2199-2205—1996.
G. Colombo of al., “Cannabinoid modulation of intestinal propulsion in mice”,Eur. J. Pharmacol. 344, 67-69, 1998.
M. A. Casu at al., “Differential distribution of functional cannabinoid CB1receptors in the mouse gasstroenteric tract”,Eur. J. Pharmacol. 459, 97-105, 2003.
Y. Nagakura et al., “Compounds possessing 5-HT3receptor antagonistic activity inhibit intestinal propulsion in mice”.Eur. J. Pharmacol. 311, 67-72, 1996.
Katoch-Rouse of al., “Synthesis, Structure-Activity Relationship, and Evaluation of SR141716 Analogues: Development of Central Cannabinoid Receptor Ligands with Lower Lipophilicity”, J. Med. Chem. 46, 642-645, 2003.
XP-002340680—Database Accession No. BRN: 837518 & Chem. Heterocycl, Compd., 9, 1374, 1973.
XP-002340681—Database Accession No. BRN: 828894 & Chem. Heterocycl. Compd., 9, 1374, 1973.
XP-002340682—Database Accession No. BRN: 181189 & Gazz. Chim. Ital., 88, 879-896, 1958.
XP-002349683—Database Accession No. BRN: 248827 & Gazz. Chim. Ital., 88, 879-896, 1958.
XP-002340684—Database Accession No. BRN: 6874802 & Farmaco Ed. Sci., 40(4), 259-271, 1985.
XP-002340685—Database Accession No. BRN: 303837 & Gazz. Chim. Ital., 89, 964-976, 1959.
Yanborisov et al., “Synthesis and Pharmacological Characterization of Heteroylpyruvic Acids and Their Derivatives”, Phar. Chem. J., 32(9), 480-482, 1998.

Affiliated with

Also associated with

Rating

Pharmaceutical compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4203226